<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Prescribing Advice for GPs</title>
	<atom:link href="http://www.prescriber.org.uk/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.prescriber.org.uk</link>
	<description>An NHS Prescribing Advisers&#039; Blog</description>
	<lastBuildDate>Tue, 14 May 2013 08:34:52 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>SMC Update - May 2013</title>
		<link>http://www.prescriber.org.uk/2013/05/smc-update-may-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/05/smc-update-may-2013/#comments</comments>
		<pubDate>Tue, 14 May 2013 08:34:52 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1234</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Abiraterone (Zytiga&#174;) has been rejected for use in the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy. The manufacturer failed to make a submission but plan to [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/05/smc-update-may-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MTRAC Reviews - February 2013</title>
		<link>http://www.prescriber.org.uk/2013/05/mtrac-reviews-february-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/05/mtrac-reviews-february-2013/#comments</comments>
		<pubDate>Mon, 13 May 2013 07:45:28 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1233</guid>
		<description><![CDATA[MTRAC issued two new Commissioning Support reviews in February 2013. The reviews cover dapagliflozin and insulin degludec for the treatment of diabetes. The dapagliflozin (Forxiga&#174;) summary advises that this drug is suitable for prescribing in primary care following initiation by a practitioner with a special interest in diabetes. Although the evidence is relatively strong it [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/05/mtrac-reviews-february-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccination Programme Update for 2013</title>
		<link>http://www.prescriber.org.uk/2013/05/vaccination-programme-update-for-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/05/vaccination-programme-update-for-2013/#comments</comments>
		<pubDate>Thu, 02 May 2013 08:44:25 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1232</guid>
		<description><![CDATA[The Department of Health has announced several changes to the national vaccination programme to include protection against flu, shingles and diarrhoea. The JCVI has previously recommended the addition of rotavirus vaccine to the childhood vaccination schedule. This infection currently causes around 140,000 cases of diarrhoea in the under 5s each year with 10% of these [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/05/vaccination-programme-update-for-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update - April 2013</title>
		<link>http://www.prescriber.org.uk/2013/04/drug-safety-update-april-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/04/drug-safety-update-april-2013/#comments</comments>
		<pubDate>Tue, 30 Apr 2013 07:25:00 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1231</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for April 2013 (PDF). This issue contains drug safety advice informing clinicians of the potential risk of error with insulin degludec (Tresiba&#174;) due to it being available in two strengths. Clinicians are urged to ensure that the correct insulin product and strength [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/drug-safety-update-april-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE Guidance - April 2013</title>
		<link>http://www.prescriber.org.uk/2013/04/nice-guidance-april-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/04/nice-guidance-april-2013/#comments</comments>
		<pubDate>Wed, 24 Apr 2013 10:20:15 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1230</guid>
		<description><![CDATA[The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of April 2013. This month there are four technology appraisals that impact upon primary care. The Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (Xolair&#174;) technology appraisal recommends this treatment as an option for treating severe persistent confirmed [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/nice-guidance-april-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Guidance on Patient Specific Directions</title>
		<link>http://www.prescriber.org.uk/2013/04/guidance-on-patient-specific-directions/</link>
		<comments>http://www.prescriber.org.uk/2013/04/guidance-on-patient-specific-directions/#comments</comments>
		<pubDate>Mon, 22 Apr 2013 15:41:47 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1229</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency has published guidance on patient specific directions (PSDs) in response to a number of enquiries about the use of PSDs in healthcare settings. The guidance answers some frequently asked questions and includes a definition of a PSD. It also clarifies what information is needed on a PSD, how [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/guidance-on-patient-specific-directions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BNF 65</title>
		<link>http://www.prescriber.org.uk/2013/04/bnf-65/</link>
		<comments>http://www.prescriber.org.uk/2013/04/bnf-65/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 15:09:38 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1228</guid>
		<description><![CDATA[The 65th Edition of the British National Formulary has been published and it is currently being distributed in the NHS. New or revised content in this version includes updated advice in the following areas: Updated guidance on pain management in palliative care Updated advice on the management of hereditary angioedema Revised guidance on the treatment [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/bnf-65/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update - April 2013</title>
		<link>http://www.prescriber.org.uk/2013/04/smc-update-april-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/04/smc-update-april-2013/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 14:40:52 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1227</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Insulin degludec (Tresiba&#174;) has been rejected for use in the treatment of diabetes mellitus in adults. The manufacturer failed to make a sufficiently robust economic case. Insulin glargine (Lantus&#174;) has been accepted for restricted use in the treatment of diabetes mellitus [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/smc-update-april-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OneTouch Verio glucose meters recalled</title>
		<link>http://www.prescriber.org.uk/2013/04/onetouch-verio-glucose-meters-recalled/</link>
		<comments>http://www.prescriber.org.uk/2013/04/onetouch-verio-glucose-meters-recalled/#comments</comments>
		<pubDate>Thu, 04 Apr 2013 14:25:28 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1226</guid>
		<description><![CDATA[The manufacturer of the OneTouch&#174; Verio&#174; IQ and OneTouch&#174; Verio&#174; Pro blood glucose testing meters have written to healthcare professionals advising that these meters either fail to provide a warning or provide an incorrect result when blood glucose levels are very high. As a result users of both meters are being advised to access a [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/onetouch-verio-glucose-meters-recalled/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>QOF 2013-14</title>
		<link>http://www.prescriber.org.uk/2013/04/qof-2013-14/</link>
		<comments>http://www.prescriber.org.uk/2013/04/qof-2013-14/#comments</comments>
		<pubDate>Wed, 03 Apr 2013 12:22:06 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1225</guid>
		<description><![CDATA[The turn of the financial year brings into effect several changes to the Quality and Outcomes Framework (QOF). The changes are available in summarised form and there is also a detailed document. Particular areas of change are: Introduction of a new rheumatoid arthritis clinical domain Patients with hypertension with elevated cardiovascular risk should be prescribed [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/04/qof-2013-14/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update - March 2013</title>
		<link>http://www.prescriber.org.uk/2013/03/drug-safety-update-march-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/03/drug-safety-update-march-2013/#comments</comments>
		<pubDate>Tue, 26 Mar 2013 14:13:15 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1224</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2013 (PDF). This issue contains drug safety advice informing clinicians that dabigatran (Pradaxa&#174;) is now contraindicated in patients with prosthetic heart valves requiring anticoagulant treatment related to their valve surgery due to an increased risk of thrombosis and bleeding events. [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/03/drug-safety-update-march-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE Guidance - March 2013</title>
		<link>http://www.prescriber.org.uk/2013/03/nice-guidance-march-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/03/nice-guidance-march-2013/#comments</comments>
		<pubDate>Wed, 20 Mar 2013 09:46:29 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1216</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of March 2013. This month there is one clinical guideline that impacts upon primary care. The Hyperphosphataemia in chronic kidney disease guideline offers evidence-based advice on the care of adults, children and young people with stage 4 or 5 [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/03/nice-guidance-march-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update - March 2013</title>
		<link>http://www.prescriber.org.uk/2013/03/smc-update-march-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/03/smc-update-march-2013/#comments</comments>
		<pubDate>Tue, 12 Mar 2013 12:08:08 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1215</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Bimatoprost single-dose eye drops (Lumigan UD&#174;) has been accepted for restricted use for the treatment of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults. Use is restricted to patients who have proven sensitivity to the preservative benzalkonium [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/03/smc-update-march-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypnotics raise hip fracture risk</title>
		<link>http://www.prescriber.org.uk/2013/03/hypnotics-raise-hip-fracture-risk/</link>
		<comments>http://www.prescriber.org.uk/2013/03/hypnotics-raise-hip-fracture-risk/#comments</comments>
		<pubDate>Fri, 08 Mar 2013 12:40:00 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1214</guid>
		<description><![CDATA[JAMA Internal Medicine (formerly the Archives of Internal Medicine) has published the results of an observational study that aimed to assess the relationship between sleep medication use and injurious falls in nursing home residents. The study review data for 15,528 patients who were long stay residents in nursing homes in America with a documented hip [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/03/hypnotics-raise-hip-fracture-risk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fostair indicated for maintenance and reliever therapy</title>
		<link>http://www.prescriber.org.uk/2013/03/fostair-indicated-for-maintenance-and-reliever-therapy/</link>
		<comments>http://www.prescriber.org.uk/2013/03/fostair-indicated-for-maintenance-and-reliever-therapy/#comments</comments>
		<pubDate>Mon, 04 Mar 2013 12:56:20 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1213</guid>
		<description><![CDATA[The product license for Fostair&#174; (beclometasone and formoterol) pressurised metered dose inhaler (pMDI) has been updated with a new indication to allow use as maintenance and reliever therapy. The Summary of Product Characteristics advises that patients can take one inhalation of the inhaler regularly twice daily for maintenance and then take up to six additional [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/03/fostair-indicated-for-maintenance-and-reliever-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update - February 2013</title>
		<link>http://www.prescriber.org.uk/2013/02/drug-safety-update-february-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/02/drug-safety-update-february-2013/#comments</comments>
		<pubDate>Fri, 22 Feb 2013 10:02:45 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1212</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2013 (PDF). This update contains drug safety advice reminding clinicians of an increased risk of atypical femoral fractures have been reported rarely in patients with postmenopausal osteoporosis receiving long-term (longer than 2.5 years) treatment with denosumab 60mg (Prolia&#174;). This debug [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/drug-safety-update-february-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NICE Guidance - February 2013 [updated]</title>
		<link>http://www.prescriber.org.uk/2013/02/nice-guidance-february-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/02/nice-guidance-february-2013/#comments</comments>
		<pubDate>Wed, 20 Feb 2013 10:34:02 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1211</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of February 2013. This month there is one clinical guideline and one technology appraisal that impact upon primary care. The Fertility guideline offers evidence-based advice on the care and treatment of people with fertility problems and is an update [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/nice-guidance-february-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shortage of Isosorbide Mononitrate</title>
		<link>http://www.prescriber.org.uk/2013/02/shortage-of-isosorbide-mononitrate/</link>
		<comments>http://www.prescriber.org.uk/2013/02/shortage-of-isosorbide-mononitrate/#comments</comments>
		<pubDate>Fri, 15 Feb 2013 09:36:55 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1210</guid>
		<description><![CDATA[The Department of Health has written to colleagues advising that there are supply issues with all normal release isosorbide mononitrate due to a problem with the availability of raw materials. This issue is affecting normal release 10mg, 20mg and 40mg tablets and may continue for several months but modified release products are unaffected. Limited stock [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/shortage-of-isosorbide-mononitrate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medication error risk with Tresiba</title>
		<link>http://www.prescriber.org.uk/2013/02/medication-error-risk-with-tresiba/</link>
		<comments>http://www.prescriber.org.uk/2013/02/medication-error-risk-with-tresiba/#comments</comments>
		<pubDate>Wed, 13 Feb 2013 12:03:59 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1209</guid>
		<description><![CDATA[The manufacturer of insulin degludec (Tresiba&#174;) has written to healthcare professionals to pre-emptively warn about the potential risk of medication errors with this new product. The new insulin will be available in two strengths, 100 units/ml and 200 units/ml, and as such there is a risk of incorrect does administration should the wrong strength product [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/medication-error-risk-with-tresiba/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update - February 2013</title>
		<link>http://www.prescriber.org.uk/2013/02/smc-update-february-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/02/smc-update-february-2013/#comments</comments>
		<pubDate>Tue, 12 Feb 2013 13:58:59 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1208</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Apixaban (Eliquis&#174;) has been accepted for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. The risk factors include prior stroke or transient ischaemic attack (TIA), age 75 years [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/smc-update-february-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>QIPP Medicines Use and Procurement Update</title>
		<link>http://www.prescriber.org.uk/2013/02/qipp-medicines-use-and-procurement-update/</link>
		<comments>http://www.prescriber.org.uk/2013/02/qipp-medicines-use-and-procurement-update/#comments</comments>
		<pubDate>Tue, 05 Feb 2013 11:10:45 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1207</guid>
		<description><![CDATA[The NICE Medicines and Prescribing Centre (formerly the National Prescribing Centre) has published an update to the QIPP Medicines management options for local implementation document (PDF). The QIPP agenda is part of the Department of Health plan for delivering better value for money in the NHS. This update has revised the topic areas in the [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/02/qipp-medicines-use-and-procurement-update/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Safety Update - January 2013</title>
		<link>http://www.prescriber.org.uk/2013/01/drug-safety-update-january-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/01/drug-safety-update-january-2013/#comments</comments>
		<pubDate>Thu, 31 Jan 2013 09:57:19 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1206</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for January 2013 (PDF). This update contains drug safety advice reminding clinicians of the need to monitor cardiac function when starting or re-starting fingolimod (Gilenya&#174;). This issue clarifies that the same first-dose monitoring as for treatment initiation should be repeated if treatment [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/01/drug-safety-update-january-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tredaptive withdrawn</title>
		<link>http://www.prescriber.org.uk/2013/01/tredaptive-withdrawn/</link>
		<comments>http://www.prescriber.org.uk/2013/01/tredaptive-withdrawn/#comments</comments>
		<pubDate>Thu, 24 Jan 2013 14:22:05 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1205</guid>
		<description><![CDATA[The manufacturer of Tredaptive&#174; (Nicotinic Acid and Laropiprant) has written to healthcare professionals advising that this product is being discontinued and will not be available with effect from 18th January 2013. This medication was being studied in the HPS2-THRIVE trial. Preliminary results from the study failed to demonstrate a statistically significant reduction in cardiovascular events [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/01/tredaptive-withdrawn/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>NICE Guidance - January 2013</title>
		<link>http://www.prescriber.org.uk/2013/01/nice-guidance-january-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/01/nice-guidance-january-2013/#comments</comments>
		<pubDate>Wed, 23 Jan 2013 09:56:22 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Other]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1204</guid>
		<description><![CDATA[The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of January 2013. This month there is one clinical guideline and one technology appraisal that impact upon primary care. The Psychosis and schizophrenia in children and young people guideline offers evidence-based advice on the recognition and management of psychosis [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/01/nice-guidance-january-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMC Update - January 2013</title>
		<link>http://www.prescriber.org.uk/2013/01/smc-update-january-2013/</link>
		<comments>http://www.prescriber.org.uk/2013/01/smc-update-january-2013/#comments</comments>
		<pubDate>Tue, 15 Jan 2013 10:24:01 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Extra - Drugs]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=1203</guid>
		<description><![CDATA[The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Budesonide gastro-resistant capsule (Budenofalk&#174;) has been accepted for symptomatic relief of chronic diarrhoea due to collagenous colitis. Budesonide 9mg gastro-resistant granules (Budenofalk&#174;) have been accepted for the induction of remission in patients with active collagenous colitis. Dapagliflozin (Forxiga&#174;) has been accepted [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2013/01/smc-update-january-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
